Ventrus Biosciences, Inc. (Nasdaq: VTUS) announced the pricing of concurrent, separate underwritten offerings of (i) 5,800,000 shares of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE